Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers tracked the in situ CAR-T cells to assess their effectiveness and safety.

Amino acids play a fundamental role in regulating how cells respond to drugs. These molecules, which form proteins, act like ...

Investigating conserved signaling pathways in different cell types shows that memory is not a unique property of neurons.

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Furthermore, ablation of TREM2 or blocking the cell receptor in two different ways — using soluble fragments of the TREM2 receptor to bind lipids before they can find the TREM2 receptors on Mo-AMs or ...

Advanced imaging technologies are uncovering surprising roles for CD8+ T cells—not just in immune defense, but also in supporting tissue repair and regeneration.

Specifically, chimeric antigen receptor (CAR) T-cell therapy and T-cell redirecting bispecific antibodies (BsAbs) have represented major breakthroughs for patients, and in some patients, a potentially ...

Using protein structure prediction tools, researchers have uncovered receptor structure-function relationships to improve cell therapies.

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o ...